Patents by Inventor Marc H. Hedrick

Marc H. Hedrick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10119113
    Abstract: Systems and methods are described that are used to separate cells from a wide variety of tissues. In particular, automated systems and methods are described that separate regenerative cells, e.g., stem and/or progenitor cells, from adipose tissue. The systems and methods described herein provide rapid and reliable methods of separating and concentrating regenerative cells suitable for re-infusion into a subject.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: November 6, 2018
    Assignee: CYTORI THERAPEUTICS, INC.
    Inventors: Marc H. Hedrick, John K. Fraser, Michael J. Schulzki, Bobby Byrnes, Grace Carlson, Ronda Elizabeth Schreiber, Isabella Wulur
  • Patent number: 9872877
    Abstract: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: January 23, 2018
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Patent number: 9849149
    Abstract: Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: December 26, 2017
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Publication number: 20170281771
    Abstract: Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.
    Type: Application
    Filed: March 17, 2017
    Publication date: October 5, 2017
    Inventors: John K. Fraser, Marc H. Hedrick, Min Zhu, Brian M. Strem, Eric Daniels, Isabella Wulur
  • Publication number: 20170136067
    Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.
    Type: Application
    Filed: November 28, 2016
    Publication date: May 18, 2017
    Inventors: Marc H. Hedrick, John K. Fraser, Susan L. Riley, Ronda E. Schreiber
  • Publication number: 20170136069
    Abstract: The present invention relates to a device comprising a cell carrier portion containing regenerative cells, e.g., stem and progenitor cells, and a cell carrier containment portion. The device is useful for the treatment of bone related disorders, including spinal fusion related disorders and long bone or flat bone related defects. The device may be used in conjunction with disclosed automated systems and methods for separating and concentrating regenerative cells.
    Type: Application
    Filed: December 1, 2016
    Publication date: May 18, 2017
    Inventors: Marc H. Hedrick, John K. Fraser, Susan Lynn Riley, Joseph W. Tai
  • Publication number: 20170136066
    Abstract: Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.
    Type: Application
    Filed: November 28, 2016
    Publication date: May 18, 2017
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Patent number: 9597395
    Abstract: Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: March 21, 2017
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Min Zhu, Brian M. Strem, Eric Daniels, Isabella Wulur
  • Patent number: 9511096
    Abstract: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: December 6, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Patent number: 9511094
    Abstract: Cells present in adipose tissue are used to stroke and stroke related diseases and disorders in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: December 6, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Brian M. Strem
  • Patent number: 9504718
    Abstract: Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 29, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Patent number: 9504716
    Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: November 29, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: Marc H. Hedrick, John K. Fraser, Susan Lynn Riley, Ronda Elizabeth Schreiber
  • Patent number: 9492483
    Abstract: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: November 15, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Patent number: 9480718
    Abstract: Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: November 1, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Publication number: 20160310540
    Abstract: Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.
    Type: Application
    Filed: July 6, 2016
    Publication date: October 27, 2016
    Inventors: John K. Fraser, Marc H. Hedrick, Eric Daniels
  • Patent number: 9463203
    Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: Marc H. Hedrick, John K. Fraser, Susan L. Riley, Ronda E. Schreiber
  • Publication number: 20160143952
    Abstract: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.
    Type: Application
    Filed: November 30, 2015
    Publication date: May 26, 2016
    Inventors: John K. Fraser, Marc H. Hedrick
  • Publication number: 20160137970
    Abstract: Systems and methods are described that are used to separate cells from a wide variety of tissues. In particular, automated systems and methods are described that separate regenerative cells, e.g., stem and/or progenitor cells, from adipose tissue. The systems and methods described herein provide rapid and reliable methods of separating and concentrating regenerative cells suitable for re-infusion into a subject.
    Type: Application
    Filed: October 12, 2015
    Publication date: May 19, 2016
    Inventors: Marc H. Hedrick, John K. Fraser, Michael J. Schulzki, Bobby Byrnes, Grace Carlson, Ronda Elizabeth Schreiber, Isabella Wulur
  • Publication number: 20160113967
    Abstract: The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects.
    Type: Application
    Filed: September 21, 2015
    Publication date: April 28, 2016
    Inventors: Marc H. Hedrick, John K. Fraser
  • Publication number: 20150376572
    Abstract: The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue.
    Type: Application
    Filed: December 23, 2014
    Publication date: December 31, 2015
    Inventors: Adam J. Katz, Ramon Llull, J. William Futrell, Marc H. Hedrick, Prosper Benhaim, Hermann Peter Lorenz, Min Zhu, Patricia Zuk, Peter H. Ashjian